Menu
Transient protein interaction networks are fundamental to cellular function. Designing “molecular glues” that influence cellular pathways by binding at protein interfaces provides a unique opportunity to revolutionize drug discovery. This is Gandeeva’s mission. We identify key druggable transient protein interactions using advanced AI approaches, visualize them with atomic resolution cryo-EM and custom design precision molecular glues that bind specifically at these protein interfaces. This strategy allows us to discover drugs against previously inaccessible targets.
Gandeeva’s technology includes three proprietary platform modules working in concert to shorten the timeline for drug discovery.
Target Selection Engine
An AI- and cryo-EM-based approach to identify and structurally validate a continuous stream of druggable target-protein interactions
Cryo-EM Engine
Computational and empirical identification of "hits" prioritized with cryo-EM structural validation
Drug Discovery Engine
Rapid structure-enabled lead optimization at the speed of chemistry
Our approach enables us to tackle a wide spectrum of therapeutic targets ranging from protein-protein complexes,
nucleic acid-protein complexes, to membrane proteins.
Gandeeva’s technology includes three proprietary platform modules working in concert to shorten the pipeline from drug discovery to clinical stage:
Target Selection Engine
An AI- and cryo-EM-based approach to identify and structurally validate a continuous stream of druggable target-protein interactions.
Cryo-EM Engine
Computational and empirical identification of therapeutic hits prioritized with cryo-EM structural validation.
Drug Discovery Engine
Rapid structure-enabled lead optimization at the speed of chemistry.
Our approach enables us to tackle a wide spectrum of therapeutic targets ranging from protein-protein complexes,
nucleic acid-protein complexes, to membrane proteins.
